Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Premier Sponsor of CannX Brazil Conference; HempMeds® Mexico President Invited as Featured Speaker

SAN DIEGO, Nov. 13, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that subsidiary HempMeds® Brasil will be a premier sponsor at the CannX Brazil Conference in São Paulo on Nov. 12-14. HempMeds® Mexico President Raul Elizalde has been invited to be a featured speaker at the conference and will present on the benefits of cannabidiol (CBD) hemp oil and the evolving legal landscape of cannabis in Latin America.

The conference will bring together some of the most important leaders in the cannabis industry from around the world, including leading industry experts from Brazil and Latin America, as well as local healthcare and government authorities. The goal of the conference is to collaborate and find new ways to enhance the research and medical support of cannabis in Latin America and gain support for future cannabis legislation.

“I am honored to be a featured speaker at this incredible educational event,” said HempMeds® Mexico President Raul Elizalde. “Supporting CBD research and education throughout the world is one of our top priorities and this event will allow us to offer essential information on the wellness benefits of CBD and connect with the world’s leading medical professionals and researchers.”

During the event, Elizalde will be presenting on the panel “How Cannabis Therapeutic Use Can Help in the Promotion of Health and Quality of Life,”, which aims to educate health professionals, educators and researchers about CBD and its many uses. The panel will take place on Nov. 14 from 2:00-3:30 pm.

“We’re proud to be one of the most trusted suppliers of reliable CBD in Brazil and hope that attendees of this event will take home valuable information about HempMeds, furthering our national footprint,” said HempMeds® Brasil Vice President Caroline Heinz. “We’re also thankful for the opportunity to speak with the international research community as well as Brazilian medical professionals who will be prescribing our CBD products to their patients.”

HempMeds® Brasil was the first company to receive an import permit for CBD in Brazil and, after a series of historic rulings, Brazilian Health Regulatory Agency ANVISA removed CBD from Brazil’s prohibited substance use listremoved the substance’s import tax and is now actively subsidizing the cost of CBD for those who need financial assistance.

To learn more about the event, please visit

About HempMeds® Brasil

HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil works on additional approvals for other indications.

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.


Public Relations Contact:

Andrew Hard

Chief Executive Officer CMW Media

P. 888-829- 0070

[email protected]